AstraZeneca To Share FibroGen’s Anemia Compound With Astellas, But Will Hoard China For Itself
This article was originally published in PharmAsia News
Executive Summary
In FibroGen’s FG-4592, AstraZeneca sees a potential strong seller in China where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.